Table 2.
Summary of studies using irinotecan-based therapy for patients with relapsed/refractory Ewing sarcoma.
| Author [Ref] | N | IRN dose and schedule | Route of IRN administration | TEM dose | Other drugs | Response rate (complete + partial) | Comments |
|---|---|---|---|---|---|---|---|
| Bisogno et al. [38] |
13 | 20 mg/m2/d × 5 × 2 | IV | — | — | 38% | Study limited to soft tissue PNET patients |
| Cosetti et al. [37] |
3 | 20 mg/m2/d × 5 × 2 | IV | — | — | 0 | |
| Bomgaars et al. [29] | 16 | 50 mg/m2/d × 5 | IV | — | — | 0 | |
| Casey et al. [36] |
20 | 10 mg/m2/d × 5 × 2 | IV | 100 mg/m2/d × 5 | — | 63% | Median TTP = 8.3 months |
| Wagner et al. [35] |
14 | 10–20 mg/m2/d × 5 × 2 | IV | 100 mg/m2/d × 5 | — | 29% | 50% of patients received at least 6 courses before progression |
| Anderson et al. [44] | 25 | 10 mg/m2/d × 5 × 2 | IV | 100 mg/m2/d × 5 | — | 60% | Median TTP = 5.5 months |
| Wagner et al. [31] |
5 | 35–90 mg/m2/day | PO | 100–150 mg/m2/d × 5 | VCR | 40%* | Phase I trial using different doses and schedules |
| McNall-Knapp et al. [46] | 1 | 15 mg/m2/d × 5 × 2 | IV | 100 mg/m2/d × 5 | VCR | 100% (n = 1) |
*Two of five patients had initial responses, but came off study prior to repeat imaging VCR, vincristine; TEM, temozolomide; IRN, irinotecan; TTP, time to progression.